Neuroprotective treatments

Advances in understanding the molecular mechanisms of necrobiosis and therefore the pathologic process of intermittent and familial Parkinson's disease are making new opportunities for the development of Neuroprotectiveand/or neurorestorative therapies. Current therapies for Parkinson’s disease ameliorate symptoms within the early phases of disease however become less effective over time, as the underlying disease progresses. Therapies that slow the progression of Parkinson’s disease are required. However, there are comparatively few clinical trials aimed toward demonstrating neuroprotection. Many potential Neuroprotective compounds, representing a wide range of mechanisms, are out there and benefit further investigation in Parkinson’s disease.


  • Immunotherapy
  • Clearance of pathological tau
  • Secretase inhibitors & modulators
  • Neuroprotective & mitochondrial compound
  • Deep brain stimulation
  • Immunomodulators
  • Amyloid clearance
  • Cell-based therapies
  • Transcranial magnetic stimulation

Are you interested in

Mail us at

Drop us a mail for program enquiry
parkinsons@alliedconferences.org
Sponser/Exhibiting/advertising
parkinsonsdisease@alliedmeetings.com
General queries
parkinsons@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2018-2019 Allied Academies, All Rights Reserved.